Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
37.26
+1.04 (2.87%)
At close: Aug 1, 2025, 4:00 PM
37.47
+0.21 (0.56%)
After-hours: Aug 1, 2025, 4:29 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 20 analysts that cover Revance Therapeutics stock have a consensus rating of "Buy" and an average price target of $44, which forecasts a 18.09% increase in the stock price over the next year. The lowest target is $33 and the highest is $60.
Price Target: $44.00 (+18.09%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 7 |
| Buy | 4 | 4 | 4 | 4 | 5 | 6 |
| Hold | 8 | 8 | 8 | 8 | 7 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 18 | 18 | 18 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $43 → $38 | Hold | Maintains | $43 → $38 | +1.99% | Jul 30, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $56 → $49 | Strong Buy | Maintains | $56 → $49 | +31.51% | Jul 29, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $48 → $46 | Buy | Maintains | $48 → $46 | +23.46% | Jul 29, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $50 → $45 | Hold | Maintains | $50 → $45 | +20.77% | Jul 29, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $50 | Buy | Reiterates | $50 | +34.19% | Jul 29, 2025 |
Financial Forecast
Revenue This Year
2.38B
from 2.17B
Increased by 9.88%
Revenue Next Year
2.68B
from 2.38B
Increased by 12.59%
EPS This Year
2.35
from 1.76
Increased by 33.47%
EPS Next Year
2.89
from 2.35
Increased by 22.86%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.6B | 3.2B | 3.9B | ||
| Avg | 2.4B | 2.7B | 3.1B | ||
| Low | 2.2B | 2.3B | 2.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 22.0% | 34.5% | 46.1% | ||
| Avg | 9.9% | 12.6% | 15.6% | ||
| Low | 1.5% | -2.6% | -11.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.95 | 4.02 | 5.40 | ||
| Avg | 2.35 | 2.89 | 3.66 | ||
| Low | 1.65 | 2.07 | 2.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 67.6% | 71.2% | 87.0% | ||
| Avg | 33.5% | 22.9% | 26.9% | ||
| Low | -6.5% | -12.0% | -28.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.